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Pancreatic cancer is characterised by a hallmark desmoplastic response that includes upregulated expression of the extracellular
matrix, and type I collagen in particular. Recent studies indicate that pancreatic cancer cells stimulate type I collagen synthesis in
adjacent stellate cells, and that this upregulated type I collagen expression promotes the malignant phenotype in tumour cells as
defined by increased proliferation, resistance to chemically induced apoptosis, and increased tumorigenesis. The integrin specificity of
this interaction between type I collagen and tumour cells was not identified, however. In the present study, we examined eight
pancreatic cancer cell lines for adhesion, proliferation, and migration, on types I and IV collagen, fibronectin, laminin, and vitronectin, as
well as integrin expression. Our results indicate, for the overwhelming majority of cell lines, that type I collagen promotes the
strongest adhesion, proliferation, and migration relative to the other substrates tested. Utilising function-blocking monoclonal
antibodies directed against particular integrin subunits in cell adhesion and migration inhibition assays, we demonstrate further that
the malignant phenotype on type I collagen is mediated specifically by the a2b1 integrin. These results identify a2b1 integrin-mediated
adhesion to type I collagen as a potential therapeutic target in the treatment of pancreatic cancer.
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Pancreatic ductal adenocarcinoma is thought to result from a
progressive accumulation of mutations in such genes as K-ras,
CDKN2A, p53, BRCA2, p16
4ink, and SMAD4 (Bardeesy and
DePinho, 2002). The SMAD4 mutations, in particular, which result
in the constitutive activation of transforming growth factor b1
(TGFb1) signalling, are generally considered to be responsible for
the hallmark desmoplastic response, which includes upregulated
expression of the extracellular matrix (ECM), and type I collagen
in particular (Mollenhauer et al, 1987; Lohr et al, 1994; Shimoyama
et al, 1995; Linder et al, 2001; Bardeesy and DePinho, 2002; Menke
and Adler, 2002; Tempia-Caliera et al, 2002; Iacobuzio-Donahue
et al, 2003a,b).
We have previously shown that a2b1 integrin-mediated adhesion
on type I collagen promotes the malignant phenotype in FG
pancreatic cells, as defined by increased proliferation and
haptokinetic cell migration, downregulated expression and loca-
lisation of E-cadherin and b-catenin in cell–cell contacts,
increased phosphorylation of GSK3b and PKB/Akt, and down-
regulated expression of PTHrP, IL-6, and IL-8 compared to
fibronectin, type IV collagen, laminin, or vitronectin (Grzesiak
et al, 2004, 2005a). These results are in agreement with previous
studies demonstrating in Panc-1, BxPC-3, and PaTu8988s pan-
creatic cancer cells that type I collagen downregulates E-cadherin
expression, resulting in increased proliferation and migration
compared to fibronectin (Menke et al, 2001). Recently, we
extended our initial observations in FG cells by demonstrating
similar phenotypic differences in BxPC-3, Colo-357, and CFPAC
cells on type I collagen compared to fibronectin; that is, increased
haptokinetic cell migration, downregulated expression and loca-
lisation of E-cadherin and b-catenin in disrupted cell–cell
contacts, increased phosphorylation of GSK3 and PKB/Akt, and
decreased expression of PTHrP, IL-6, and IL-8. Furthermore,
functional studies with pharmacological inhibitors for GSK3 and
PKB/Akt suggest that these signalling effectors are involved in the
mechanism of a2b1 integrin-mediated regulation of the malignant
phenotype in FG cells (Grzesiak et al, 2006).
Recent studies from several other laboratories have also converged
on the hypothesis that type I collagen, in particular, plays an active
role in vitro and in vivo in the pathophysiology of pancreatic cancer
(Armstrong et al, 2004; Bachem et al, 2005). Specifically, these
studies demonstrated in vitro that pancreatic cancer cell lines
stimulated the production of type I collagen from adjacent stellate
cells, which resulted in increased cancer cell proliferation and
resistance to chemically induced apoptosis. In vivo, these studies also
showed that type I collagen expression was closely associated with
both the cancer and stellate cells, and that introduction of stellate
cells along with the tumour cells increased tumorigenesis in nude
mice. The integrin specificity of this interaction between tumour
cells and type I collagen was not identified, however.
In the present study, we surveyed a broad range of pancreatic
cancer cell lines from various tumour grades, origins, and genetic
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saberrations, for relative integrin expression, as well as adhesion,
proliferation, and haptokinetic migration on types I and IV
collagen, fibronectin, laminin, and vitronectin. Our results indicate
strong a2b1 integrin-mediated type I collagen adhesion, prolifera-
tion, and migration for all cell lines, except MiaPaCa-2, which does
not express the a2b1 collagen-binding integrin. These results
collectively suggest an active and dynamic role for the ECM,
and type I collagen in particular, in the growth, progression, and
metastasis of pancreatic cancer, and identify the a2b1 integrin as a
potential therapeutic target in the treatment of this devastating
disease.
MATERIALS AND METHODS
Cells
Seven human pancreatic adenocarcinoma cell lines, Capan-1,
CFPAC, Colo-357, AsPC-1, BxPC-3, MiaPaCa-2, and Panc-1 cells
were obtained from the American Type Culture Collection
(Rockville, MD, USA). FG cells are a fast-growing, metastatic
variant of the Colo-357 cell line (Vezeridis et al, 1990), and were
the generous gift from Dr S Silletti. The cell lines were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% foetal bovine serum (FBS) in a humidified atmosphere
containing 5% CO2 at 371C.
Antibodies
The function-blocking monoclonal antibodies directed against
particular integrin subunits and integrins used in these studies
have been described (Cheresh and Spiro, 1987; Wayner and Carter,
1987; Sonnenberg et al, 1988; Wayner et al, 1988, 1993; Fabbri et al,
1996), and include FB12 (a1), P1E6 (a2), P1B5 (a3), P1D6 (a5),
GoH3 (a6), P5D2 (b1), LM609 (avb3), P1F6 (avb5), and ASC-3 (b4)
(Chemicon International, Temecula, CA, USA). For immuno-
precipitation (IP) experiments, we used the monoclonal antibodies
described above along with rabbit polyclonal antisera against the
a5 integrin subunit, which has also been described previously
(Ruoslahti and Pierschbacher, 1987).
Cell adhesion assays
Cell adhesion assays were performed as described previously
(Ruoslahti et al, 1982). Briefly, 5 10
4 cells, serum-starved 24h
prior to assay, in 100ml of serum-free DMEM supplemented
with 1mgml
 1 bovine serum albumin (BSA) were added to each
well of nontissue culture-treated 96-well microtitre plates (Becton
Dickinson, Franklin Lakes, NJ, USA) that were previously coated
overnight at room temperature with serial dilutions of purified
ECM proteins, beginning with 100mgml
 1 through 0.79mgml
 1,
and blocked with 1mgml
 1 BSA in phosphate-buffered saline
(PBS) for 1h at 371C. Extracellular matrix proteins included bovine
types I and IV collagen, human fibronectin, mouse laminin, and
human vitronectin (Chemicon International). Plates were then
incubated for 1h at 371C, the unattached cells were removed, and
the attached cells were fixed with 3% paraformaldehyde in PBS,
stained with 0.5% toluidine blue in 3.7% formaldehyde, solubilised
with 20% sodium dodecyl sulphate, and the absorbance at 595nm
was measured using a vertical pathway spectrophotometer.
Inhibition of cell adhesion assays
Inhibition of cell adhesion assays were performed as described
previously (Grzesiak et al, 1992, 2005a). Briefly, 96-well microtitre
plates were previously coated with type I collagen (5mgml
 1) and
unbound sites blocked with 1mgml
 1 BSA as described above.
Then, 5 10
4 FG or CFPAC cells, or 2.5 10
4 AsPC-1 or BxPC-3
cells were added to each well in serum-free DMEM supplemented
with 1mgml
 1 BSA. Purified monoclonal antibodies were added at
a final concentration of 25mgml
 1 in the serum-free medium
described above. After 45min at 371C, media were removed;
attached cells were fixed, stained, destained, solubilised, and
quantified as described above.
Migration assays
Migration assays were conducted using the modified Boyden
chamber as described previously (Grzesiak et al, 1992, 2005a).
Briefly, the chamber consists of two compartments separated by
a filter, and migration was measured by counting the number of
cells crossing the membrane through pores of defined size.
Lower chambers were filled with serum-free DMEM (Invitrogen,
Carlsbad, CA, USA) supplemented with 1mgml
 1 BSA. Pore
polycarbonate membrane filters (8mM) (Neuro Probe Inc.,
Gaithersburg, MD, USA) that were coated with either type I
collagen, type IV collagen, fibronectin, laminin, or vitronectin,
each at 5mgml
 1, were then placed on top of the lower chambers,
and the upper chambers were secured in place. Upper chambers
were filled with 5 10
4 FG, AsPC-1, MiaPaCa-2, BxPC-3, or CFPAC
cells that were serum-starved 24h prior to assay, in the same
media described above. Lower chamber final volumes were 30ml
and the upper chambers were 50ml. The entire apparatus was then
incubated for 24h at 371C. After the incubation period, the filters
were fixed in methanol and stained with 0.5% toluidine blue in
3.7% formaldehyde. Excess stain was washed away with water, the
attached cells on the upper side of the filters were mechanically
removed using wet, cotton-tipped applicators, and the migratory
cells on the underside of the filters were quantitated by counting
four high-powered fields ( 100 magnification) per well using an
inverted light microscope (Olympus BH 2).
Inhibition of cell migration assays
In some experiments, migration assays were conducted as
described above, with the addition of function-blocking mono-
clonal antibodies directed against specific integrin subunits to
the upper chamber at the time cells were added. Final antibody
concentrations were 50mgml
 1 for FB12 (a1), P1E6 (a2), and P1B5
(a3), and 25mgml
 1 for P5D2 (b1). Type I collagen-coating
concentrations were 5mgml
 1 for each cell line. Cells (5 10
4)
were added to each well, except for BxPC-3 cells, which were used
at 2.5 10
4 cellswell
 1.
Immunoprecipitations
To perform IPs, antibodies (4mg) were adsorbed for 2h at room
temperature onto 25ml packed anti-mouse IgG–agarose, anti-rat
IgG–agarose or protein A–sepharose (Sigma, St Louis, MO, USA)
in IP wash buffer (50mM Tris-Hcl, pH 7.5, 0.5 M NaCl, 1mM MgCl2,
1m M CaCl2, and 0.1% Tween-20). Antibody-coated beads were
washed and 400mg protein from cell-surface-biotinylated cell
lysates was added in IP wash buffer. Protein content was
determined using the modified Bradford reagent according to
the manufacturer’s instructions (BioRad, Hercules, CA, USA).
Pancreatic cancer cell lines were cell surface biotinylated using
EZ-Linkt Sulfo-NHS-LC-Biotin (sulfosuccinimidyl-6-(biotinami-
do) hexanoate) according to the manufacturer’s instructions
(Pierce Biotechnology Inc., Rockford, IL, USA) as described
previously (Grzesiak et al, 2005b). Cell lysates were prepared as
previously described, except ethylenediaminetetraacetic acid was
removed and replaced with 1mM CaCl2 and 1mM MgCl2 (Grzesiak
et al, 2004, 2005a,b). After incubation overnight at 41C, the beads
were washed six times with IP wash buffer, 50ml2  NU–PAGE
sample buffer was added (Invitrogen, Carlsbad, CA, USA) samples
were incubated 15min at 701C, and 25ml of sample was carefully
loaded, separated on 12% NU–PAGE gels under nonreducing
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sconditions, and transferred to nitrocellulose. After blocking with
3% BSA in PBS/0.1% Tween-20 overnight at 41C, membranes were
incubated with horseradish peroxidase-conjugated streptavidin
(1:25000 dilution; Pierce Biotechnology Inc.) for 30min at room
temperature, followed by washing, and detection of peroxidase
activity using chemiluminescence according to the manufacturer’s
instructions (Amersham Biosciences, Little Chalfont, UK).
Proliferation assays
The 96-well polystyrene culture dishes, not treated for tissue
culture, were coated with type I collagen, type IV collagen,
fibronectin, laminin, or vitronectin at the following concentra-
tions: for AsPC-1 cells – types I and IV collagen at 5mgml
 1,
fibronectin at 25mgml
 1, laminin at 15mgml
 1, and vitronectin at
5mgml
 1; for CFPAC cells – types I and IV collagen at 5mgml
 1,
fibronectin and laminin at 25mgml
 1, and vitronectin at
10mgml
 1; for BxPC-3 cells – types I and IV collagen at 5mgml
 1,
and fibronectin, laminin, and vitronectin each at 15mgml
 1; for
MiaPaCa-2 cells – types I and IV collagen at 10mgml
 1, fibronectin
at 25mgml
 1, laminin at 15mgml
 1, and vitronectin at 10mgml
 1;
and for FG cells – types I and IV collagen at 5mgml
 1, laminin at
10mgml
 1, fibronectin at 25mgml
 1, and vitronectin at 10mgml
 1.
These coating concentrations promote maximal adhesion for each
cell line as shown in Figure 1. Twenty-four hour, serum-starved
pancreatic cancer cells (5 10
3well
 1) were cultured under serum-
free conditions on these ECM substrata over a 4-day time course.
At the indicated time points, triplicate proliferation determina-
tions were quantified by measuring the absorbance at 450nm and
subtracting the value obtained for each cell line on each ECM
substrate at initial seeding using CellTiter 96 Aqueous One
Solution Cell Proliferation Assayt reagent according to the
manufacturer’s instructions (Promega, Madison, WI, USA). This
reagent is composed of a novel tetrazolium compound (methyl-p-
tolyl sulfide), and an electron coupling reagent, phenazine
ethosulphate.
Statistics
Statistical significance (Po0.05) was determined using two-tailed
Student’s t-tests.
RESULTS
Type I collagen promotes maximal cell adhesion in
pancreatic cancer cell lines
We first tested the panel of commonly used pancreatic cancer cell
lines shown in Table 1, which covers all tumour grades and genetic
mutations, and includes cell lines derived from primary tumours,
ascites, and liver and lymph node metastases, in serum-free
adhesion assays on the stromal ECM proteins, type I collagen,
fibronectin, and vitronectin, and the basement membrane
proteins, type IV collagen and laminin. Figure 1 demonstrates
that in seven of eight cell lines tested, type I collagen promoted the
strongest cell attachment relative to the other ECM proteins, and
did so at much lower concentrations compared to the other ECM
proteins tested. Only MiaPaCa-2 cells did not attach to type I
collagen, nor did they attach to type IV collagen, even at the
highest coating concentrations. Attachment to fibronectin was also
quite strong in all the cell lines, except for the grade 1 tumour cell
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Figure 1 Type I collagen promotes maximal adhesion of pancreatic cancer cell lines compared to other ECM proteins. Cell adhesion assays were
conducted as described in Materials and Methods with Capan-1, CFPAC, Colo-357, FG, AsPC-1, BxPC-3, MiaPaCa-2, and Panc-1 cells. CI, & – type I
collagen; CIV, D – type IV collagen; Fn, m – fibronectin; Ln, K – laminin; and Vn, ’ – vitronectin. Results are expressed as the mean7s.e.m. from two
independent experiments conducted in duplicate. Nonspecific adhesion to BSA7s.e.m. is also noted for each cell line. 100%¼maximal absorbance at
595nm for each cell line and each set of ECM proteins.
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slines, Capan-1 and CFPAC, and the grade 2 cell line, AsPC-1, which
showed only weak to moderate attachment. Laminin adhesion was
moderate to weak in all cell lines tested. Adhesion of pancreatic
cancer cell lines on vitronectin was the most variable. Relative
to the other ECM proteins, FG, Colo-357, BxPC-3, and CFPAC
cell adhesion to vitronectin was limited, while AsPC-1, Capan-1,
Panc-1, and MiaPaCa-2 adhesion to vitronectin was very strong. A
trend towards increased vitronectin adhesion with increasing
tumour grade was apparent, with both grade 3-derived cell lines,
MiaPaCa-2 and Panc-1, attaching strongly to vitronectin. Relative
to the other cell lines, BxPC-3, CFPAC, and Panc-1 exhibited the
strongest adhesion, regardless of substrate (unpublished observa-
tions).
Type I collagen promotes maximal proliferation of
pancreatic cancer cell lines
We next examined the differential effect of the ECM on pancreatic
cancer cell proliferation. Using ECM protein concentrations that
promoted maximal cell adhesion for each of the substrates with
five representative cell lines still representing all three tumour
grades, we conducted 96h proliferation assay time-course studies
under serum-free conditions. All cell lines tested grew well
throughout the 4-day time course, even in the absence of serum,
as long as the cells were given an ECM substrate to which they
could attach. Figure 2 shows a strong direct correlation between
pancreatic cancer cell adhesion and proliferation, with AsPC-1,
BxPC-3, CFPAC, and FG cells demonstrating maximal proliferation
on type I collagen relative to the other ECM proteins examined.
MiaPaCa-2 cells, by contrast, showed essentially no proliferation
on either type I or type IV collagen. Visual inspection confirmed
that MiaPaCa-2 cells were found as nonadherent floating
aggregates when cultured on either of the collagens (unpublished
observations).
Table 1 Origin, grade, and genetic mutations of pancreatic cancer cell
lines (Peng et al, 2002; Sipos et al, 2003; Monti et al, 2004).
Cell line Origin Grade K-ras p53 p16
ink4A DPC4/Smad4
Capan-1 Liver metastasis 1 mut mut mut mut
CFPAC Liver metastasis 1 mut mut mut mut
Colo-357 Lymph node metastasis 2 mut w.t. w.t. mut
FG Lymph node metastasis 2 mut w.t. w.t. mut
AsPC-1 Ascites 2 mut mut Mut w.t.
BxPC-3 Primary 2 w.t. mut mut mut
MiaPaCa-2 Primary 3 mut mut mut w.t.
Panc-1 Primary 3 mut mut mut w.t.
mut¼mutated; w.t.¼wild type.
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Figure 2 Type I collagen promotes maximal pancreatic cancer cell proliferation. The 96-well polystyrene culture dishes, not treated for tissue culture,
were coated with type I collagen, type IV collagen, fibronectin, laminin, or vitronectin as described in Materials and Methods. Twenty-four hour, serum-
starved MiaPaCa-2, AsPC-1, BxPC-3, CFPAC, and FG cells (5 10
3well
 1) were cultured under serum-free conditions on the indicated ECM substrates
over a 4-day time course. At the indicated time points, triplicate determinations were quantified for each cell line on each substrate by measuring the
absorbance at 450nm and subtracting the value obtained at initial seeding (T¼0) using CellTiter 96 Aqueous One Solution Cell Proliferation Assayt
reagent according to the manufacturer’s instructions (Promega, Madison, WI, USA). Data presented represent the mean7s.e.m. from two independent
experiments.
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sType I collagen promotes maximal haptokinetic cell
migration in pancreatic cancer cell lines
We next examined all of our cell lines for haptokinetic cell
migration on the ECM. As opposed to chemotaxis, where cell
migration is stimulated by a growth factor gradient, haptokinetic
migration reflects the natural ability of the substrate to promote
cell movement. Figure 3 demonstrates that type I collagen
promotes maximal haptokinesis in all the SMAD4-mutated cell
lines, including Capan-1, CFPAC, BxPC-3, Colo-357, and FG, cells.
Interestingly, MiaPaCa-2, AsPC-1, and Panc-1 cells, which exhibit
wild-type SMAD4, and exhibit only moderate cell adhesion on
laminin (Figure 1), migrated maximally on that substrate. Panc-1
and AsPC-1 cells also showed significant migration on type I
collagen, whereas MiaPaCa-2 cells exhibited no haptokinesis on
the substrate. Vitronectin and fibronectin promoted relatively
weak haptokinesis on all cell lines tested, although the two
substrates promoted very strong cell adhesion in some cases
(Figure 1). Relative to the other cell lines tested, BxPC-3 cells
exhibited the most haptokinesis followed by Panc-1 and CFPAC,
regardless of substrate (unpublished observations). Taken to-
gether, these results demonstrate that type I collagen promotes a
phenotype that is consistent with malignancy in the majority of
our pancreatic cancer cell lines, as defined by maximal cell
adhesion, proliferation, and migration, relative to the other ECM
proteins tested. These data also identify laminin as a strong
migratory substrate in those cell lines lacking an SMAD4 mutation
(AsPC-1, MiaPaCa-2, and Panc-1).
The collagen-binding, a2b1 integrin mediates the
malignant phenotype in pancreatic cancer cell lines
Integrins mediate the adhesion of cells to the ECM (Ruoslahti et al,
1994), and we have recently demonstrated in a limited study with
FG cells that the a2b1 integrin mediates type I collagen adhesion
and proliferation (Grzesiak et al, 2004, 2005a). Presently, we
conducted IPs of all eight cell lines for relative expression of the a1,
a2, a3, a5, a6, b1, and b4 integrin subunits, and the avb3 and avb5
integrins. Figure 4 demonstrates that the a2 integrin subunit is
expressed by all of our pancreatic cancer cell lines, except for
MiaPaCa-2 cells, which do not attach, proliferate, or migrate on
types I or IV collagen under serum-free conditions (Figures 1–3).
Interestingly, Figure 4 also demonstrates that the collagen-binding
a1 integrin subunit is expressed in all cell lines with TGFb1-
activating SMAD4 mutations, including Capan-1, CFPAC, Colo-
357, FG, and BxPC-3, but not in those cells expressing wild-type
SMAD4, including AsPC-1, MiaPaCa-2, and Panc-1. All cell lines
appear to be immunoreactive to varying degrees for the a3, a5, a6,
b1, and b4 integrin subunits, as well as the avb3 and avb5 integrins.
These integrin expression results are generally consistent with
relative strength of adhesion and migration, BxPC-3, CFPAC, and
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Figure 3 Type I collagen promotes maximal pancreatic cancer cell migration. Pore polycarbonate membrane filters (8mm) were coated with either type I
collagen, type IV collagen, fibronectin, laminin, or vitronectin, at 5mgml
 1. Lower chambers of the modified Boyden chamber were filled with 30mlwell
 1 of
serum-free DMEM supplemented with 1mgml
 1 BSA, the coated filters were then placed on top of the lower chambers, and the upper chambers were
secured in place. Upper chambers were filled with 5 10
4 FG, AsPC-1, MiaPaCa-2, BxPC-3, or CFPAC cells that were serum-starved 24h prior to assay, in
50ml of the same media described above. The entire apparatus was then incubated for 24h at 371C. After the incubation period, the filters were fixed in
methanol and stained with 0.5% toluidine blue in 3.7% formaldehyde. Excess stain was washed away with water, the attached cells on the upper side of the
filters were mechanically removed using wet, cotton-tipped applicators, and the migratory cells on the underside of the filters were quantitated by counting
four high-powered fields ( 100 magnification) per well using an inverted light microscope (Olympus BH 2). Results presented represent the mean7s.e.m.
from two independent experiments with at least three replicates per substrate for each cell line. 100%¼maximal cell number for each cell line and each set
of ECM proteins.
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and integrin expression.
As collagen-binding integrins have been shown to include a1b1,
a2b1, and a3b1, depending on the cell type (Ruoslahti, 1991), and
because these integrins are variously expressed by all of our cell
lines, we conducted inhibition of adhesion and migration assays
on type I collagen using function-blocking monoclonal antibodies
directed against specific integrin subunits. Figure 5A and B
demonstrate clearly that pancreatic cancer cell adhesion and
migration on type I collagen is mediated exclusively by the a2b1
integrin, and that neither the a1, a3, a5,o ra6 integrin subunits, nor
the avb3 or avb5 integrins appear to be involved in the adhesive
interactions between AsPC-1, BxPC-3, CFPAC, or FG pancreatic
cancer cells and type I collagen. Immunoprecipitation studies
shown in Figure 4 and previous studies by us and other
laboratories (Cheresh and Spiro, 1987; Wayner and Carter, 1987;
Sonnenberg et al, 1988; Wayner et al, 1988, 1993; Grzesiak et al,
1992, 2005a; Fabbri et al, 1996) demonstrate that the monoclonal
antibodies used for the type I collagen inhibition studies are
functional.
DISCUSSION
In the present study, we characterised the adhesion, proliferation,
and haptokinetic cell migration, as well as the relative integrin
expression profiles of eight pancreatic cancer cells lines comprised
of all three tumour grades, and derived from primary tumours,
liver and lymph node metastases, and ascites. We tested
physiologically relevant ECM components from the stroma,
including type I collagen, fibronectin, and vitronectin, as well as
the basement membrane proteins, type IV collagen and laminin,
for their ability to promote a malignant phenotype in pancreatic
cancer cell lines, as defined by increased adhesion, proliferation,
and migration.
The clear indication that most of our pancreatic cancer cell lines
attach, proliferate, and migrate maximally on type I collagen
compared to the other ECM proteins examined is not surprising, in
that the hallmark desmoplastic reaction associated with pancreatic
adenocarcinoma, including upregulated type I collagen expression,
has been appreciated for some time now (Mollenhauer et al, 1987;
Lohr et al, 1994; Shimoyama et al, 1995; Tani et al, 1997; Kuehn
et al, 1999; Linder et al, 2001; Tempia-Caliera et al, 2002). Recent
analyses using microarray and serial analysis of gene expression
technology confirm those studies and point out the strong
expression of many other ECM genes in pancreatic cancer as well
(Iacobuzio-Donahue et al, 2003a,b; Binkley et al, 2004; Stein et al,
2004).
There is growing evidence that the desmoplastic response
associated with pancreatic cancer is representative of dysregulated
normal injury repair processes that include TGFb1-stimulated
expression of type I collagen and other ECM proteins (Menke and
Adler, 2002). In fact, it has been shown in vitro that TGFb1
upregulates type I collagen expression in pancreatic cancer (Lohr
et al, 2001). Very recent studies from two independent laboratories
also provide supporting data that type I collagen, in particular,
plays an active role in vitro and in vivo in the pathophysiology of
pancreatic cancer (Armstrong et al, 2004; Bachem et al, 2005).
Specifically, these studies demonstrated in vitro that pancreatic
cancer cell lines stimulated the production of type I collagen from
adjacent stellate cells, which resulted in increased cancer cell
proliferation and resistance to chemically induced apoptosis. In
vivo, these studies also showed that type I collagen expression was
closely associated with both the cancer and stellate cells, and that
introduction of stellate cells along with tumour cells increased
tumorigenesis in nude mice. Our present results are the first to
indicate that even though there are several potential integrin
receptors expressed by our pancreatic cancer cell lines, the a2b1
integrin exclusively mediates type I collagen adhesion, prolifera-
tion, and migration.
The previous demonstrations that type I collagen is clearly
upregulated (Mollenhauer et al, 1987; Lohr et al, 1994; Shimoyama
et al, 1995; Tani et al, 1997; Kuehn et al, 1999; Linder et al, 2001;
Tempia-Caliera et al, 2002; Iacobuzio-Donahue et al, 2003a,b;
Binkley et al, 2004; Stein et al, 2004), and mediates a malignant
phenotype in pancreatic cancer in vivo (Armstrong et al, 2004;
Bachem et al, 2005), correlates directly with our present in vitro
observations, and are further extended by our demonstration that
the a2b1 integrin specifically regulates this type I collagen-mediated
phenotype in multiple pancreatic cancer cell lines. These observa-
tions collectively suggest that targeting the a2b1 integrin may have
therapeutic value in the treatment of pancreatic cancer in vivo.I n
support, inhibition of the a2b1 integrin with function-blocking
monoclonal antibodies inhibited human osteosarcoma cell (HOS)
tumour growth in SCID mice (Miura et al, 2005). In another study,
OCUM-2MD3, a human scirrhous gastric carcinoma cell line
overexpressing a2b1 and a3b1 integrins, produced peritoneal
dissemination in nude mice compared to control cells, and its
invasive ability was significantly decreased following the addition of
a2b1 or a3b1 integrin antibodies (Nishimura et al, 1996).
Our present results also identify two distinct and previously
unknown phenotypes that correlate directly with the presence or
absence of TGFb1-activating SMAD4 mutations (see Table 1). In
the five pancreatic cancer cell lines with SMAD4 mutations,
including Capan-1, CFPAC, Colo-357, FG, and BxPC-3, type I
collagen promotes maximal adhesion, migration, and proliferation.
Regarding integrin expression, these same five cell lines express
the collagen-binding a1b1 integrin. In the three cell lines
expressing wild-type SMAD4, including AsPC-1, MiaPaCa-2, and
Panc-1, maximal migration occurs on laminin and there is a
distinct absence of the a1b1 integrin. These results are in
agreement with previous results indicating that Panc-1 cells are
negative and that BxPC-3 cells are positive for the a1 integrin
subunit by FACS analyses (Lohr et al, 1996). It is intriguing that
TGFb1 treatment of the NR4 hepatocyte cell line increased the
expression of a1 integrin subunit mRNA (Serra et al, 1994),
directly correlating with our findings that cell lines with TGFb1-
activating SMAD4 mutations express the a1b1 integrin. Interest-
ingly, while the a1b1 integrin is only expressed in cell lines
- 1 (FB12)
- 3 (P1B5)
- 5 (AB1928)
- 6 (GoH3)
- 1 (P5D2)
- v3 (LM609)
- v5 (P1F6)
- 4 (ASC-3)
- 2 (P1E6)
Capan-1 CFPAC Colo-357 FG Panc-1 AsPC-1 BxPC-3 MiaPaCa-2
Figure 4 Integrin, E-cadherin, and b-catenin expression in pancreatic
cancer cell lines. Immunoprecipitations were conducted using 4mg anti-
integrin antibodies and 400mg cell-surface-biotinylated extracts from
pancreatic cancer cell lines as described in Materials and Methods.
Immunoprecipitates were separated on 12% Nu–PAGE gels under
nonreducing conditions, and protein bands were visualised using
streptavidin–HRP and chemiluminescence. Autoradiograms for each
particular integrin subunit or integrin heterodimer for each cell line are
indicated in the right-hand margin.
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antibody against a1 had no effect on pancreatic cancer cell
adhesion or migration on type I collagen either alone or in
combination with the a2 function-blocking monoclonal antibody.
Our data indicate that only the a2b1 integrin mediates type I
collagen adhesion, migration, and proliferation in pancreatic
cancer cell lines.
Immunoprecipitation results indicate that seven of the eight
pancreatic cancer cell lines express the collagen-binding a2b1
integrin. While expression of the a2 integrin subunit has been
demonstrated previously for most of these cell lines (Lohr et al,
1996; Sawai et al, 2001; Miyamoto et al, 2004), to our knowledge,
this is the first demonstration that the CFPAC cell line is also a2
integrin subunit positive. These results are in agreement with
reports using other pancreatic cancer cell lines, including PC-2, -3,
and -44, PaTu 8988S, HPAF, Capan-2, PaTu 8902, and PaTu-2 cells,
which also demonstrated type I collagen adhesion and a2 integrin
subunit expression (Mollenhauer et al, 1987; Weinel et al, 1992).
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Figure 5 The a2b1 integrin mediates pancreatic cancer cell adhesion and haptokinetic migration on type I collagen. Inhibition of AsPC-1, BxPC-3, CFPAC,
and FG cell adhesion and migration assays were conducted using 96-well plates or 8mM polycarbonate membranes coated with 5mgml
 1 type I collagen as
described in Materials and Methods. Function-blocking monoclonal antibodies directed against the indicated integrins or integrin subunits were added at final
concentrations ranging between 25 and 50mgml
 1 as described in Materials and Methods for each antibody and each cell line. (A) Cell adhesion and (B)
haptokinetic cell migration.
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ing, in multiple cell lines, the relative strength of type I collagen
adhesion, proliferation, and migration compared to the other
physiologically relevant ECM proteins tested in these studies.
These results also rule out a contribution from the a1b1 integrin in
mediating tumour cell adhesion to type I collagen in pancreatic
cancer.
In agreement with previous studies, our results also indicate that
MiaPaCa-2 cells do not attach to types I or IV collagen, and they do
not express the a2 integrin subunit (Sawai et al, 2001; Miyamoto
et al, 2004). In fact, it has been recently shown that attempts to
grow MiaPaCa-2 cells on type I collagen substrates resulted in
apoptosis (Vaquero et al, 2003). Our results extend these early
findings, demonstrating for the first time that MiaPaCa-2 cells are
negative for a1 integrin subunit expression as well. Additionally,
we demonstrate that MiaPaCa-2 cells attach and proliferate
strongly on vitronectin and fibronectin, and are very migratory
on laminin.
Adhesion of pancreatic cancer cell lines to vitronectin yielded
the most wide-ranging results, with MiaPaCa-2, Capan-1, AsPC-1,
and Panc-1 exhibiting strong adhesion and proliferation (MiaPa-
Ca-2 and AsPC-1), and CFPAC, FG, Colo-357, and BxPC-3
exhibiting weak adhesion and proliferation (CFPAC, FG, and
BxPC-3). It is also interesting that three of the four cell lines
demonstrating strong vitronectin adhesion, including Panc-1,
MiaPaCa-2, and AsPC-1, also express wild-type SMAD4.
In summary, these studies using a broad panel of pancreatic
cancer cell lines strongly implicate the a2b1 integrin in the
promotion of the malignant phenotype on type I collagen in
pancreatic cancer, as defined by increased adhesion, proliferation,
and migration. These results further identify the a2b1 integrin as a
potential therapeutic target in the treatment of this devastating
disease. These studies also identify dramatic differences in integrin
expression and ECM substrate preferences in pancreatic cancer cell
lines expressing wild-type vs mutated SMAD4. Future studies will
aim at the inhibition of pancreatic cancer growth, progression, and
metastasis in our orthotopic mouse models using function-
blocking monoclonals against a2b1 integrin function.
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